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Abstract
We have devised a chemocentric informatics methodology for drug discovery integrating
independent approaches to mining biomolecular databases. As a proof of concept, we have
searched for novel putative cognition enhancers. First, we generated Quantitative Structure-
Activity Relationship (QSAR) models of compounds binding to 5-hydroxytryptamine-6 receptor
(5HT6R), a known target for cognition enhancers, and employed these models for virtual
screening to identify putative 5-HT6R actives. Second, we queried chemogenomics data from the
Connectivity Map (http://www.broad.mit.edu/cmap/) with the gene expression profile signatures
of Alzheimer’s disease patients to identify compounds putatively linked to the disease. Thirteen
common hits were tested in 5-HT6R radioligand binding assays and ten were confirmed as actives.
Four of them were known selective estrogen receptor modulators that were never reported as 5-
HT6R ligands. Furthermore, nine of the confirmed actives were reported elsewhere to have
memory-enhancing effects. The approaches discussed herein can be used broadly to identify novel
drug-target-disease associations.
Introduction
Target-oriented drug discovery is one of the most popular modern drug discovery
approaches1–5. Target-oriented approaches rely on established functional associations
between activation or inhibition of a molecular target and a disease. Modern genomics
approaches including gene expression profiling, genotyping, genome-wide association, and
mutagenesis studies continue to serve as useful sources of novel hypotheses linking genes
(proteins) and diseases and providing novel putative targets for drug discovery.
In recent years, functional genomics approaches have been increasingly complemented by
chemical genomics6–11 i.e., large scale screening of chemical compound libraries in multiple
biological assays12–16. The resulting data (either generated within chemical genomics
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centers or collected and curated from published literature) have been deposited in many
public and private databases such as the NIMH Psychoactive Drug Screening Program Ki
Database (Ki-DB)17, PubChem18, ChEMBL19, WOMBAT20 and others (reviewed by21).
Various in silico techniques have been exploited for analyzing target-specific biological
assay data. A recent publication by Kortagere and Ekins22 could serve as a good summary of
most common target-oriented computational drug discovery approaches including: (1)
structure based virtual screening (docking and scoring) using either experimentally
characterized (with X-ray or NMR) or predicted by homology modeling structure of the
target protein, (2) chemical similarity searching using known active compounds as queries,
(3) pharmacophore based modeling and virtual screening, (4) quantitative structure-activity
relationship (QSAR) modeling, and (5) network or pathway analysis.
Data resulting from large-scale gene or protein expression or metabolite profiling (often
collectively referred to as 'omics' approaches23–26) can be explored not only for specific
target identification but also in the context of systems pharmacology to identify networks of
genes (or proteins) that may collectively define a disease phenotype. For example, ‘omics’
data can be used to query genes or proteins, or post-translationally modified states of
proteins that are over- (or under-) expressed in patients suffering from a particular disease.
These types of data can be found in a number of public repositories such as the Gene
Expression Omnibus (GEO)27;28, GEOmetadb29, the Human Metabolome Database
(HMDB)30;31, Kinase SARfari32, the Connectivity Map (cmap)33;34, the Comparative
Toxicogenomics Database (CTD)35, STITCH36;37, GenBank38;39, and others. Importantly,
many of these databases integrate, in some way, chemical effects on biological systems
providing an opportunity to explore diverse computational approaches, individually or in
parallel, to modeling and predicting the relationships between drug structure, its bioactivity
profile in short term biological assays, and its effects in vivo.
Recently, a group of scientists at the Broad Institute established the Connectivity Map
(cmap) database to catalog the biological responses of a large number of diverse chemicals
in terms of their gene expression profiles33. Indeed, insights into disease pathology and
underlying mechanisms can be revealed by the disease ‘gene signature’, i.e., those genes
whose expression varies consistently between patients and healthy individuals (controls)40.
Gene-expression profiling has been often applied to elucidate the mechanisms underlying
the roles of biological pathway in a disease41;42, reveal arcane subtypes of a disease,43;44
and estimate cancer prognosis45;46. At the same time, the treatment of cultured human cells
with chemical compounds that target a disease can produce a drug related ‘gene signature’,
i.e., differential expression profile of genes in response to the chemical40;47–49. It has been
shown that examining the correlations between gene expression profiles characteristic of a
disease and those modulated by drugs may lead to novel hypotheses linking chemicals to
either etiology or treatments for a disease33;43;50–56.
The cmap database provides an unusual but intriguing example of what we shall call a
chemocentric ‘omics’ database and methodology for generating independent and novel drug
discovery hypotheses. Indeed, there exists a wealth of information buried in the biological
literature and numerous specialized chemical databases17–20;57 linking chemical compounds
and biological data (such as targets, genes, experimental biological screening results; cf.58).
The chemocentric exploration of these sources, either individually or in parallel opens up
vast possibilities for formulating novel drug discovery hypotheses concerning the predicted
biological or pharmacological activity of investigational chemical compounds or known
drugs. The integration and cross-validation of such independent structural hypotheses can
increase the quality of the final hit list of predicted actives.
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Herein, we describe a novel integrative chemocentric informatics approach to drug
discovery that integrates computational hits generated from independent analysis of both
traditional target-specific assay data and those resulting from large scale genomics and
chemical genomics studies. As a proof of concept, we have focused on the Alzheimer’s
disease as one of the most debilitating neurodegenerative diseases with complex etiology
and polypharmacology. We have considered and cross-examined two independent but
complementary approaches to the discovery of novel putative anti-Alzheimer’s drugs. First,
we have employed a traditional target-oriented cheminformatics approach to discovering
anti-Alzheimer’s agents. We have built QSAR models of ligands binding to 5-
hydroxytryptamine-6 receptor (5-HT6R). It has been shown that 5-HT6R antagonists can
produce cognitive enhancement in animal models59, and it has been suggested that this
receptor may be a potential target for treating cognitive deficits in Alzheimer's disease60. We
have then used models developed with the rigorous predictive QSAR modeling workflow
established and implemented in our laboratory61 for virtual screening (VS) of the World
Drug Index database (WDI)57 and DrugBank62 to identify putative cognition enhancing
agents as compounds predicted to interact with 5-HT6R. Second, we have explored
(chemo)genomic data available from the cmap project33;34 to link chemical compounds and
the Alzheimer’s disease without making explicit hypotheses about target-specific
mechanisms of action, i.e., treating Alzheimer’s disease as a complex polypharmacological
disease.
We then cross-examined and combined common hits regarded as structural hypotheses
resulting from both approaches towards common integrated hits supported by two
independent lines of computationally-based evidence. Thirteen common hits (Figure 1) were
tested in 5-HT6R binding assays using the resources of the NIMH Psychoactive Drug
Screening Program (PDSP)17 and ten were confirmed experimentally as actives.
Unexpectedly, we found that the confirmed actives included several selective estrogen
receptor modulators (SERMs) that were never reported earlier as 5-HT6R ligands suggesting
that they may be potential cognitive enhancers. Indeed, we have identified clinical evidence
in biomedical literature in support of this hypothesis. We believe that approaches discussed
in this study can be applied to a large variety of systems to identify novel drug-target-disease
associations.
Materials and Methods
Integrative Chemocentric Informatics Approach
We have devised an integrative workflow focused on the discovery of new drug candidates
and finding new uses for existing drugs by integrating predictions generated from different
data types and methods. Currently, the workflow (Figure 2) incorporates three major
components: (1) a module for QSAR-based VS of chemical libraries to identify new ligands
for target proteins, (2) a network-mining module to identify small molecule therapeutics for
specific diseases without necessarily knowing the underlying target-specific mechanism; this
module explicitly relies on cmap33;34, an external online database
(www.broadinstitute.org/cmap/) that links the effects of different drugs and diseases using
gene expression profiles, and (3) ChemoText58, an in-house repository of relationships
between chemicals, diseases, proteins, and biological processes. The first two modules have
been employed extensively for studies reported herein.
We start our study with identifying established disease-target associations (e.g., 5-HT6R is
implicated in treating Alzheimer’s disease). Then we mine the biological literature and
specialized databases to extract ligands known to interact with the biological target of
interest. Activity data could be either binding affinities (Ki values) or functional data (IC50
values for agonists and antagonists). Binding and functional data could be either continuous
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(e.g., Ki and IC50 values) or categorical (e.g., active vs. non-active or agonist vs. antagonist)
in nature. At this stage we use our QSAR-based VS module (see Figure 3; predictive QSAR
workflow) to generate robust predictive QSAR models that can be employed for VS of
chemical libraries to derive new hypotheses about putative actives (agonists or antagonists).
In parallel, we mine the biological literature for gene signatures associated with the disease
and/or for all related protein targets implicated in the disease state. We use these disease
related genes and proteins to query specialized databases to extract information about
disease-protein (gene)-chemical connections. For example, we use disease gene signatures
to query the cmap for putative treatments, and we use related proteins to query ChemoText
for related chemicals to establish new disease-protein (gene)-chemical connections. After a
thorough analysis of all data, we select hit compounds that are expected to be novel
treatments for the disease (cf. Figure 2).
Finally, we integrate hypotheses derived from the QSAR-based VS approach with those
derived from text/network mining. The common structural hits identified by both
approaches are considered for further experimental validation. We assume that the quality of
the final structural hypotheses resulting from independent approaches to knowledge mining
in chemocentric databases is intrinsically better than that in any computational hit generated
in respective independent studies.
Databases and Datasets
PDSP Ki-DB—PDSP Ki-DB17 (http://pdsp.med.unc.edu/pdsp.php) includes published
binding affinities (Ki) of drugs and chemical compounds for receptors, neurotransmitter
transporters, ion channels, and enzymes. It currently lists more than 47000 Ki values for
more than 700 molecular targets. Ki-DB represents a curated, fully searchable database of
both published data and data internally-derived from the NIMH-PDSP. The experimental
data for Alzheimer’s disease related target 5-HT6R were extracted from the PDSP Ki-DB
available in the public domain. The complete 5-HT6R dataset included binding affinity data
for 250 compounds
World Drug Index (WDI)—WDI57 is an authoritative database for marketed and
developmental drugs providing information about internationally recognized drug names,
synonyms, trade names, trivial names, trial preparation codes, compound structures, and
activity data. Herein, we used WDI for QSAR-based VS to identify putative 5HT6R ligands.
DrugBank—DrugBank62 (http://www.drugbank.ca) is a unique bioinformatics and
cheminformatics resource that combines detailed drug data (i.e., chemical, pharmacological,
and pharmaceutical) with comprehensive drug target information (i.e., sequence, structure,
and pathway). Currently, the database contains nearly 4800 drug entries. Herein, we used
DrugBank for virtual screening using QSAR models to identify putative 5HT6R ligands
among known drugs
PubChem—PubChem18 is a public repository of chemical structures and their activities
obtained from a variety of biological assays. The PubChem compound repository presently
contains more than 30 million unique structures with biological property information
provided for many of the compounds. Herein, we used PubChem to obtain all chemical
structures for our datasets in SDF file format.
The Connectivity Map (cmap)—The cmap33;34 (http://www.broadinstitute.org/cmap/) is
a unique database for using chemical genomics in drug discovery framework. It provides
researchers with a systematic solution for the discovery of the functional connections
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between drugs, genes, and diseases. The database used in this study (cmap build 02)
included 7056 genome-wide expression profiles representing 6100 individual treatment
instances with 1309 bioactive small molecules (i.e., drugs and other biologically active
compounds). All gene expression profiles included in the cmap were derived from treating
cultured human cells (MCF7, PC3, HL60, SKMEL5, HepG2, SHSY5Y) with chemical
compounds.
NetAffx—NetAffx63;64 (http://www.affymetrix.com) gene ontology mining tool is a web-
based, interactive tool that permits traversal of the gene ontology graph in the context of
microarray data. It accepts a list of Affymetrix probe sets and renders a gene ontology graph
as a heat map colored according to significance measurements. It also details and annotates
probe sets on Affymetrix GeneChip microarrays. In this study we used NetAffx to populate
our disease gene signatures with Affymetrix U133A probe sets.
ChemoText—ChemoText58 is an in-house repository of chemical entities, and activity
terms (indicating biological effects) extracted from annotations provided in Medline records.
This resource has different applications in drug discovery projects. First, we can use
ChemoText in a discovery-mode to formulate independent hypotheses about chemical-
disease associations according to Swanson’s ABC rule.65 Secondly, we can use it as an
information retrieval tool to gather relevant data about chemical-protein (or gene)-disease
connections derived from biomedical literature. In this study, we used ChemoText to
retrieve all available biological information about the final computational hits predicted by
our integrative approach. This analysis helped us in assessing the novelty of the produced
hypotheses and in validating some of them.
Computational Methods
1. QSAR Modeling and QSAR-based Virtual Screening
Preprocessing of the Dataset: We used a workflow for chemical data curation that was
developed in our lab and published recently66. First, all molecules were “washed” using the
“Wash Molecules” application in MOE (v.2007.09)67. Using this tool, we processed
chemical structures by carrying out several standard operations including 2D depiction
layout, hydrogen correction, salt and solvent removal, chirality and bond type normalization
(all details can be found in the MOE manual67). Second, we used ChemAxon’s Standardizer
(v. 5.2.6)68 to harmonize the representation of aromatic rings. Third, we checked all
normalized molecular structures in the dataset for duplicated compounds using the “Sort
Unique Entries” application in MOE. Our analysis resulted in the detection and removal of
56 duplicate chemical entries leaving 194 unique normalized molecular structures. These
194 unique, organic compounds, including 102 actives and 94 non-actives (see Table S1 of
Supporting Information) were used for binary QSAR studies. We assigned the ‘activity’
class for each compound based on its Ki value(s) obtained from the PDSP and according to
PDSP specifications as reported at the PDSP website (http://pdsp.med.unc.edu/).
Compounds with Ki values ≥ 10 µM were considered non-actives and assigned to class 0,
whereas compounds with Ki values < 10 µM were considered actives and assigned to class
1.
Dataset Division for Model Building and Validation: Following our predictive QSAR
modeling workflow (summarized in a recent review61) all QSAR models generated to
classify 5-HT6R actives vs. non-actives were validated by predicting both test and external
validation sets. The original dataset of 194 compounds (102 actives and 92 non-actives) was
randomly split into 5 different subset of nearly equal size to allow for external 5-fold cross
validation (CV)69;70 where the dataset compounds were ranked from 1 to n (n = total
number of compounds in the dataset) then the first compound went to the external set and
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the following 4 compounds were included in the modeling set. Then the 6th compound went
to the external set and the following 4 compounds went to the modeling set. This process
was continued until all compounds were divided between the external and the modeling sets.
In this protocol, each subset including 20% of the original dataset was systematically
employed as the external validations set while the remaining 80% of the compounds
constituted the modeling set.
Another level of internal validation was achieved by comparing model performance for
training and test sets. This approach is always employed as part of our predictive QSAR
modeling workflow61;71 to emphasize the fact that training-set-only modeling is not
sufficient to obtain reliable models that are externally predictive72. Thus, for each collection
of descriptors, the modeling sets (each including 80% of the original dataset) were further
partitioned into multiple chemically diverse training and test sets of different sizes using the
Sphere Exclusion method implemented in our laboratory73. Only models with external
predictive accuracy for test sets above certain threshold (see Selection and Validation of
QSAR Models in Supporting Information) were retained for the consensus prediction of the
external validation sets. Finally, models that demonstrated the highest predictive power for
both evaluation sets were used in consensus fashion for virtual screening of external
compound libraries. The model building and validation approach is illustrated schematically
in Figure 3.
Combinatorial QSAR Modeling: Two QSAR modeling approaches of different nature were
used concurrently to generate classification models for 5-HT6R actives vs. non-actives
(Figure 3). The first approach relied on k-nearest neighbor (kNN) model optimization
method combined with Dragon descriptors, and the second employed classification based on
association (CBA) and subgraphs (SG) descriptors. All details about QSAR methods,
evaluation of generated models, and consensus prediction are available in the Supporting
Information.
Virtual Screening: To identify putative ligands, validated consensus kNN-Dragon models
generated for 5-HT6R ligands were used for virtual screening of both the 59000 molecules
within the WDI57 chemical library and 1300 DrugBank62 compounds included in the cmap
database. The identified hits (by consensus agreement between all accepted kNN-Dragon
models) were then evaluated additionally using CBA-SG classifier when it was a need to
reduce the size of the VS library generated with kNN-Dragon models.
2. Biological Network Mining
Querying the cmap with Alzheimer’s Disease Gene Signatures: The cmap33;34 was used
to discover unexpected connections between chemicals, genes and the Alzheimer’s disease
by generating a detailed map that links gene patterns associated with Alzheimer’s to
corresponding patterns produced by drug candidates and a variety of genetic perturbations
included in the cmap database. The effects of different drugs and diseases are described
using “genomic signatures" — the full complement of genes that are turned on and off by a
particular drug or disease. We start by querying the online database (cmap:
http://www.broadinstitute.org/cmap/) with gene signatures characteristic of the Alzheimer’s
disease. Then, a computer program, that uses sophisticated pattern-matching methods,
matches the barcodes based on the patterns shared among Alzheimer’s gene signature and
drugs included in the cmap.
Alzheimer’s Disease Gene Signatures: In order to query the cmap, a disease gene
signature should exist. Two lists of genes are required to perform the query: a list of up-
regulated genes and a list of down-regulated genes characteristic of a disease. Query
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signatures can be obtained from two major sources: (1) biological literature: gene signatures
of diseases can be extracted through the National Library of Medicine’s PubMed system
(http://www.ncbi.nlm.nih.gov/pubmed), (2) GEO27;28 database: a gene expression/molecular
abundance repository supporting MIAME74 (Minimum Information About a Microarray
Experiment) compliant data submissions, and a curated, online resource for gene expression
data browsing, query and retrieval. For the purposes of this study, two independent reports
of gene-expression changes in brain tissues from Alzheimer’s patients were used to derive
gene signatures (i.e., lists of genes up- and down- regulated in Alzheimer’s disease) to query
the cmap. Signature 1 (from hippocampus) consisted of 40 genes reported by Hata, R. et
al75, and signature 2 (from cerebral cortex) consisted of 25 genes reported by Ricciarelli, R.
et al76. NetAffx was then used to map gene symbols and Unigene identifiers to populate
gene signature lists with Affymetrix U133A probe sets to query the cmap.
3. Hypothesis Integration—We cross-examined and integrated structural hypotheses
generated independently from both QSAR-based VS and biological network mining efforts
to identify and accept common hits only. This step of hypotheses integration was based on
structural identity comparisons. All chemical structures of cmap compounds were retrieved
from DrugBank62 using their DrugBank identifiers. Identical structures only were then
accepted for further analysis. All chemical structures labeled as identical were also subjected
to a manual curation step where structures and names of the chemical compounds were
compared in different databases to make sure they both refer to the same chemical entity.
Common hits were then considered for further experimental validation.
4. Experimental Validation in Radioligand Binding Assays—Final common hit
compounds from QSAR-based VS and cmap negative connections with Alzheimer’s were
purchased and submitted to PDSP for experimental target validation. The experimental
details of radioligand binding assays are available at the PDSP website17.
Results and Discussion
QSAR Modeling of 5-HT6R Actives vs. Non-actives
kNN with Dragon descriptors was employed to classify modeling set compounds into 5-
HT6R actives vs. non-actives. As part of 5-fold cross validation process, the dataset was
divided, into five subsets of nearly equal size. Four parts (selected systematically) formed
modeling sets with 155 compounds each and the fifth part, containing 39 compounds, was
considered as a validation set. Each of the five modeling sets derived to collect 5-fold CV
statistics was additionally subdivided into multiple training and test sets (28-40 divisions)
using the Sphere Exclusion algorithm as described in Methods. Multiple QSAR models were
generated independently for all training sets and applied to the test sets. Generally, we
accept models with CCR values above or equal to 0.70 for both the training and test sets.
However, because we were able to generate thousands of acceptable models, we used more
conservative criteria (i.e., CCRtrain and CCRtest above or equal to 0.90) for model selection
to predict external compounds. Basically, each train/test split, kNN will generate at least one
model. Increasing the "Number of Runs" option will multiply the number of generated
models. The "descriptors per model" parameter can again multiply the number of generated
models; if kNN tries to make a model with 5 descriptors, a model with 6 descriptors, and a
model with 7 descriptors in each case, the total number of models will be tripled. So, to
calculate the number of models that will be generated: (Number of train-test splits) *
(Number of Runs) * (Number of different values "Descriptors per Model" can take). This is
an important thing to consider before starting a modeling run: Too few models will be
unlikely to create a good predictor, while too many models can take a very long time to
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generate. If the dataset is a high quality dataset (i.e. there are very good distinctive features
between actives and inactives) then we may be able to generate thousands of acceptable
models. However, these models differ in their statistical parameters. See “Selection and
validation of QSAR models” in Supporting Information.
Results of Y-randomization tests confirmed that kNN-Dragon classification models with
CCRtrain and CCRtest values above or equal to 0.90 were robust. None of the models with
randomized class labels of the training set compounds had CCRtrain and CCRtest above 0.65
or CCRevs above 0.55 for any split.
The CBA method was used to classify the dataset using SG descriptors. The modeling sets
(described above) were used to build the classifier in CBA77 using an initial pool of about
400 SG descriptors. The classifier gave an average CCRtrain of 0.92 (i.e., the average
resulted from five different tests). Then, the external validation sets consisting of 39
compounds were used to assess the robustness of the classifier. The average CCRtest was
0.78, which is not as high the CCR value for the training set, but is still statistically
acceptable.
Clearly, kNN (mean CCRevs = 0.92) performed better than CBA (mean CCRevs = 0.78) on
the external validation sets. Therefore, we chose to use kNN-Dragon models for VS of
external drug libraries. Nevertheless, we maintained CBA-SG models as an additional filter
to suggest smaller sets of compounds as 5-HT6R putative actives selected from the list of
virtual hits obtained with kNN-Dragon models and therefore predicted by both models as
putative actives.
QSAR-based Virtual Screening
Since our models proved reasonably accurate based on external validation sets, we used the
best models to mine two external databases of approved and potential drugs for putative 5-
HT6R ligands. The use of applicability domain assures reliable predictions by the models.
Therefore, we used two types of applicability domains in the virtual screening of compound
databases. First, we used a global applicability domain that acted as a filter and ensured
some level of global similarity between the predicted compounds and the compounds in the
modeling set. Second, we defined a local applicability domain for each of the individual
classification models.
We first screened the WDI database57 of about 59000 compounds (approved or
investigational drugs) (Figure 5). This original collection had many duplicates (i.e., many
salt forms for the same chemical entity), and these duplicates were removed using MOE. We
also removed all compounds that were duplicates of those molecules that were included in
our modeling and external validation sets. Dragon descriptors were generated for the
remaining 46859 unique compounds in the database; of these, 9732 compounds were
excluded because Dragon was unable to calculate at least one of the descriptors generated
for the modeling set. The remaining 37127 compounds were then subjected to a global
applicability domain filter for the modeling set using a strict Z cutoff of 0.5 (which formally
places the allowed pairwise distance threshold at the mean of all pairwise distance
distribution for the training set plus one-half of the standard deviation). Then, all kNN-
Dragon models with CCRtrain and CCRtest above or equal to 0.70 were employed in
consensus fashion to predict 1500 compounds remaining after several filtering steps, which
resulted in the identification of the 600 predicted actives. In an effort to reduce the number
of hits, we have generated SG descriptors for these 600 molecules and applied the CBA-SG
classifier which filtered out half of these compounds, leaving 300 compounds as putative
actives for 5-HT6R. None of these hits was tested in this study since we explicitly focused
on compounds from DrugBank62 that were employed in the cmap project. These VS hits
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from WDI should be viewed as hypothetically active compounds awaiting the experimental
confirmation; the list of the top scoring hits is included with the Supporting Information
(Table S2).
Additionally, we screened 1300 DrugBank compounds included in the cmap database.
Dragon descriptors were computed for 1273 unique compounds. These compounds were
then subjected to a global applicability domain filter for the modeling set using a strict Z
cutoff of 0.5. Consequently, we placed the allowed pairwise distance threshold at the mean
of all pairwise distance distribution for the training set plus one-half of the standard
deviation which resulted in 577 predictions within the applicability domain. Next, validated
consensus kNN-Dragon models (i.e., all models with CCRtrain and CCRtest above or equal to
0.90) were used to predict these 577 compounds, resulting in the identification of 140
unique compounds predicted to be 5-HT6R actives. We did not apply the CBA-filter here
because, for the subsequent integration with the cmap mining results, we wanted to explore
a larger set of all 140 compound hits (i.e., putative 5-HT6R actives) included in the cmap
datasets predicted by kNN-Dragon models.
Searching the Connectivity Map for Potential Anti-Alzheimer’s Agents
We used two gene signatures for the Alzheimer’s disease (designated as S1 and S2) to query
the cmap database in an attempt to link genes associated with the disease to potential
therapeutic agents. These two signatures were based on two independent rank-ordered gene
lists provided by two different Gene Set Enrichment Analysis (GSEA) studies75;76. The two
disease signatures were compared with predefined signatures of therapeutic compounds
included in the cmap and ranked according to a connectivity score (ranging from +1 to −1),
representing relative similarity to the disease gene lists. The connectivity score itself is
derived using a nonparametric, rank-based, pattern-matching strategy based on the
Kolmogorov-Smirnov statistic78. Connectivity scores are calculated using the online tools
available at the cmap (http://www.broadinstitute.org/cmap/). All instances in the database
are then ranked according to their connectivity scores; those at the top (+) are most strongly
correlated to the query signature and looked at as disease causes, and those at the bottom (−)
are most strongly anticorrelated and considered as possible therapeutics.
The majority of chemicals included in the cmap database are represented by multiple
independent replicates. Most compounds are profiled in three different cell lines, some at
different concentrations. These are called ‘instances’ for the same chemical and defined as
“a treatment and control pair and the list of probe sets ordered by their extent of differential
expression between this treatment and control pair”79. The instance is the basic unit of data
and metadata in cmap. Instances of the same compound might have similar or dissimilar
connectivity scores with the query signature. We have higher confidence in the derived
connections when gene signatures are conserved across diverse cell types and experimental
settings. However, Lamb and colleagues33;34 indicated that the nonconsistent scoring of
different instances of the same chemical may represent either (1) a cellular-context
dependent difference in activity, (2) a concentration-discriminated effect, or (3) poor
reproducibility between replicates. Therefore, ‘best’ connections are those where multiple,
autonomous instances of the same chemical have consistently high (or low) scores.
However, inconsistently scoring compounds should not necessarily be dismissed since their
significance as potential treatments for a disease can be boosted by additional evidence, such
as predictions from QSAR models.
In this study, we were interested in compounds whose chemogenomics profiles were
negatively correlated with the Alzheimer’s disease gene signatures. Hits with statistically
significant, negative connectivity scores could be potential treatments for the Alzheimer’s
disease; however, the list of negatively correlated molecules might be long and must be
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analyzed carefully before suggesting hypotheses of possible mechanisms for controlling or
mediating the disease. Examples of top negative connections with both signatures S1 and S2
are shown in Tables 1 and 2, respectively (see Tables S2 and S3 in Supporting Information
for full listings of connections and their connectivity scores). Although the two gene
signatures (i.e., for the Alzheimer’s disease) used to query the cmap shared no common
genes, both queries resulted in a common list of negative connections that were given a
higher confidence in our studies. All chemical structures for each chemical compound
included in the cmap were obtained from the DrugBank62 and mapped based on the
DrugBank identifiers provided by the cmap database.
Hypothesis Generation: Integrating Independent Hypotheses from QSAR-Based VS and
cmap Analysis
We combined hypotheses produced from two different datasets and using two different
computational methods (Figure 2): (1) QSAR-based datamining of chemical databases in an
effort to identify novel ligands for 5-HT6R, and (2) Network-mining using two signatures
for Alzheimer’s disease to query the cmap and identify possible anti-Alzheimer’s
therapeutics. Our procedure for integrating hypotheses was based on structural identity for
chemical compounds derived from both approaches mentioned above. Compounds with
negative connectivity scores, representing genes expressed in an opposite fashion to the
imported Alzheimer’s disease query—which implies their potential benefits to be candidate
treatments, were compared with 5-HT6R hits predicted from QSAR-based VS, and identical
compounds were regarded as common hits.
The primary goal for integrating hit lists produced by two independent approaches in this
study was initially to overcome some of the inherent hit scoring problems in classification
QSAR, and achieve higher success rates in experimental testing of the VS hits. In other
words; we often select for further experimental validation those QSAR hits with consensus
scores above or equal to 0.90 (referred to as consensus scores in Methods). However, many
novel scaffolds that are significantly different (i.e., structurally and possibly, therapeutically)
from the training set compounds, might have lower consensus scores ranging from 0.50 to
0.90 despite the fact that they might be actives too. Thus, this process of integrating
hypotheses derived independently from different types of data and using multiple prediction
methods, allowed us to fish out these low-confidence QSAR hits (that yet could be highly
important ligands) for further analysis. As a result, we posit that integrating independent
hypotheses is likely to improve the overall experimental success rates of hit compounds
identified in silico.
Scoring and Integrating Structural Hypotheses to Identify Putative Anti-Alzheimer’s
Agents
Our method for integrating hit lists was derived from a combination of voting and statistical
metrics. In the first step, we used two different scoring functions to rank the computational
hits generated independently from both QSAR and cmap. In the QSAR study, we used the
kNN ‘consensus score’ which takes into account the total number of models used to predict
compound’s activity, and the number of models that predicted the compound to belong to a
specific class correctly. We considered all computational hits that had an average predicted
value (i.e., consensus score) above or equal to 0.50 for further inspection. Our analysis
resulted in 140 putative 5-HT6R actives among cmap compounds and with kNN consensus
scores ranging from 0.50–1.00 (see Figure 7)
On the other hand, we used the connectivity scores33 to rank the hits resulting from querying
the cmap with Alzheimer’s disease gene signatures. Because we were interested in
identifying novel treatments for Alzheimer’s disease, we ranked hits with larger (−)
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connectivity scores at the top and gave them higher confidence. Such compounds were
hypothesized to have higher chances to reverse the Alzheimer’s gene signatures and
therefore might have immense therapeutic value in Alzheimer’s disease. We considered for
further analysis all compounds that had at least one instance of negative connection with any
of the two gene signatures used to query the cmap (S1 and S2) so that not to miss any
important connections. Our analysis resulted in identifying 881 negative connectivity
instances with S1 and 861 instances with S2 (Figure 6).
Finally, we combined the hypotheses generated from both QSAR and cmap analyses and
accepted common hits only. We identified 97 compounds that were both predicted to be
active at 5-HT6R and had at least one instance of negative connectivity with S1 and 106
compounds that had at least one instance of negative connectivity with S2. Accepting only
common hits among S1 and S2 resulted in 73 putative hits (see Figure 7). At this stage we
applied a manual curation where we inspected all available data for these 73 hits. Each of
the 73 common hits had three scores (kNN consensus score, cmap connectivity score with
S1, and cmap connectivity score with S2) to be considered in the final decision to prioritize
hits for further testing. Therefore, we estimated the average connectivity scores for all
predicted hits across all treatment instances for each of the S1 and S2 hits. Then we
excluded those compounds that had high positive connectivity scores in some treatment
instances of the same compound. Finally, we retained 39 compounds that had acceptable
negative average connectivity scores at least with one signature (see Figure 7). We
hypothesized that these compounds could be tested as putative 5-HT6R hits and potential
cognition enhancing agents in the Alzheimer’s disease. One of the final 39 hits, vinpocetine,
worth special attention as there is a new evidence that this compound may play a role in the
treatment of Parkinson's disease and Alzheimer’s disease80;81. Details on all these 39 VS
hits are provided in Tables 3 and 4.
Each of the 39 common hits had three scores (kNN consensus score, cmap connectivity
score with S1, and cmap connectivity score with S2) to be considered in the final decision to
prioritize hits for further experimental testing. We plotted the mean connectivity scores vs.
kNN QSAR consensus scores generating separate plots for S1 and S2 (see Figure 8) to
analyze these hits in further details.
Additionally, another level of confidence was achieved (besides considering both kNN CS
and cmap scores) by giving more emphasis to molecules that belonged to the same
pharmacological or therapeutic group or had very high structural similarity to hits of higher
confidence. This step permitted the retrieval of some compounds that had less significant
negative connectivity scores with the disease (e.g., null connectivity or even low positive
connectivity scores in few instances). We noticed that the 39 putative actives belonged to
several major therapeutic groups (see Table 4): antipsychotics, antidepressants, anti-
histamines, selective estrogen receptor modulators (SERMs) and calcium channel blockers.
Among these groups, predicting SERMs to have activity at 5-HT6R was the most surprising.
Hypothesis Testing: Evaluation of Computational Hits at Human Cloned 5-HT6 Receptors
Common hits from QSAR-VS studies and cmap were taken forward for biological
validation, in binding assays, for 5-HT6 receptor. As discussed above, we identified 39
chemicals, out of 59000 molecules included in the WDI57,and 1300 compounds included in
the cmap, as consensus hits and putative actives for 5-HT6R with higher chances of having
potential cognition enhancement effects in Alzheimer’s disease; none of these hits was
included in the training set used to develop QSAR models. Then, we prioritized twelve
compounds from a list of 39 molecules plus an additional compound; a SERM that was
among the top QSAR-VS hits that was not included in the cmap (1-1357, see Tables 3 and 5)
for further experimental validation in 5-HT6R radioligand binding assays. It should be noted
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that compound 12 was tested because it was a SERM predicted with a high CS of 0.93 and
we wanted to test it because three other SERMS were among our common hit list of 39
compounds. Our final selection was based on different criteria: (1) we tested some
compounds with high consensus scores and stronger negative connectivity with Alzheimer’s
disease, (2) some compounds were selected because they belonged to the same therapeutic
class as several other predicted hits and were not known before to bind to 5-HT6R such as
selective estrogen receptor modulators (SERMs) (e.g. 1, 11 and 12), (3) we tested some
compounds with low kNN CS (e.g., 10 having a kNN CS of 0.58) if other hits that belonged
to the same therapeutic class had high consensus scores (e.g., 11 and 12 having kNN CS
above to or equal 0.93 and 1 having a kNN CS of 0.91), (4) we also tried to test predictions
that had strong negative connectivity scores with one query signature but had much weaker
negative connectivity with the second signature to see if there is one specific signature that
was generating better results.
We found that ten of these thirteen predicted actives were confirmed experimentally to
inhibit 5-HT6R radioligand binding thereby achieving a success hit rate of 77 % in this
proof-of-concept study (see Table 5). One of these ten confirmed hits was clozapine, which
is known to bind 5-HT6R but was not included in our training set. Binding affinity (Ki)
values for the nine predicted hits were in the range 17 – 4125 nM, with six compounds
having Ki values < 1 µM. These six highest affinity compounds were: 3 (Ki=17 nM)17, 4
(Ki=105 nM, Figure 9 (A)), 2 (Ki=112 nM, Figure 9 (B)), 13 (Ki=169 nM, Figure 9 (C)), 8
(Ki=214 nM, Figure 9 (D)) and 10 (Ki=750 nM, Figure 9 (E)).
Among the tested compounds, we found that compounds having negative connectivity
scores and kNN CS above 0.90 were all true actives at 5-HT6R achieving a success rate of
100%. We also found that lowering the threshold to 0.50 resulted in 3 false positives which
decreased the success rate down to 77 %. It was strikingly important that we were able to
prioritize a VS hit (i.e., 10) with very low kNN CS of 0.56 and insignificant negative
connectivity scores with Alzheimer’s (see Table 5) and validate that this compound was a
true active of 5-HT6R and a potential cognition enhancer. This is a clear example on the
importance of integrating independent hypotheses to increase the confidence of otherwise
less significant computational hits.
Mining of the biomedical literature using ChemoText identified possible neuroprotective, in
addition to cognitive- and memory-enhancing, effects for most of the computational hits (see
Table 6), although there is no evidence that 5-HT6R –active compounds are neuroprotective.
The list of all 39 compounds predicted by our integrative approach as putative 5-HT6R
actives with possible anti- Alzheimer’s effects is shown in Table 5.
SERMs Identified as 5-HT6R ligands
Several selective estrogen receptor modulators (SERMs) were predicted as 5-HT6R ligands
and also had negative connections with the Alzheimer’s disease gene signatures. 1, 10 and
11 had negative connections with Alzheimer’s disease gene signatures in the cmap
database33;34. 12 was not included in the cmap but was predicted as 5-HT6R active by
QSAR-based VS. Although anti-Alzheimer’s effects of these drugs were observed
previously and attributed to their modulation of estrogen receptors (ERs), the evidence about
ER modulators or hormone replacement therapy in postmenopausal women to prevent or
treat the Alzheimer’s disease has been inconclusive and sometimes even contradictory82–84.
Although postmenopausal estrogen depletion is a known risk factor for Alzheimer’s disease,
estrogen-containing hormone therapy initiated during late postmenopausal period does not
improve episodic memory (an important early symptom of Alzheimer's disease), leads to no
improvement or adverse effect on overall cognitive performance and Alzheimer’s disease in
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postmenopausal women84–86, and it increases the risk of dementia83;84. Be that as it may,
there is still substantial evidence from both pre-clinical and human studies that ovarian
steroids have significant effects on neuroregulatory pathways87–94. However, critical gaps
exist in our knowledge of both the effects on brain function of declining ovarian steroid
secretion during reproductive aging, and the role of ovarian steroid hormone therapy in the
prevention or treatment of brain diseases82.
Raloxifene Identified as a 5-HT6R Antagonist and Agent with Potential Utility in
Alzheimer’s Disease
Raloxifene is a selective estrogen receptor modulator used to prevent or treat osteoporosis;
recently it was also approved by the FDA as an anti-cancer drug for reducing the risk of
invasive breast cancer in postmenopausal women95. It was one of the low confidence
QSAR-based VS hits because of the low structural similarity with modeling set compounds.
Therefore, we would have avoided testing this compound if it had not been predicted from
the cmap to have a strong negative connection with Alzheimer’s disease. Another level of
confidence was obtained from having other compounds that belonged to the same
pharmacological group (SERMs) that were predicted as 5-HT6R actives with high
confidence (i.e., consensus scores above 0.90) and had negative connections with
Alzheimer’s disease. This example highlights the value of the integrated informatics
approach in increasing the hit rates of QSAR-based VS. Experimental testing had indeed
confirmed that raloxifene binds to 5-HT6R with a Ki of 750 nM (Table 5, Figure 9 (E)).
Yaffe and coworkers examined the data from the Multiple Outcomes of Raloxifene
Evaluation (MORE) trial and indicated that raloxifene given at a dose of 120 mg/day, but
not 60 mg/day, led to reduced risk of cognitive impairment in postmenopausal women96.
Additionally, recent studies pointed out that raloxifene enters the brain in relevant quantities
and exerts a measurable effect in humans97. It is possible that raloxifene’s anticipated anti-
Alzheimer’s effects could be due to complex polypharmacological profile effecting several
protein targets and signaling pathways involved in memory, cognition, inflammation,
oxidative control and other important biological processes underlying the Alzheimer’s
disease etiology, and not limited to its canonical targets (i.e., estrogen receptors). Currently,
raloxifene is in phase II clinical trials for Alzheimer’s disease in postmenopausal women98.
This example can thus be considered as a proof of concept for the ability of our approach to
increase the confidence in the identified hits that are structurally and biologically dissimilar
to training set compounds.
Conclusions
We have developed a novel integrative chemocentric informatics approach that could be
used as a tool for generating and cross-validating drug discovery hypotheses. Our approach
integrates different in silico strategies and different data types and sources to increase the
confidence in the final hypotheses. The study design was composed of three major parts: (1)
QSAR-based datamining of chemical libraries to identify new ligands for target proteins, (2)
Network-mining to identify chemicals that could treat specific diseases; and (3) Integrating
hits derived from (1) and (2).
This approach has been applied to study the 5-HT6R system in relation to cognition
enhancement strategies which may be useful for Alzheimer’s and, perhaps, similar diseases
with impaired cognition. Disease gene signatures for Alzheimer’s disease have been used to
query the cmap database to formulate testable hypotheses about potential treatments.
Common compound hits from QSAR/VS studies against 5-HT6R and the cmap were tested
in at 5-HT6R. Our approach identified 39 drugs, as potential 5-HT6R antagonists, out of
59000 molecules included in the WDI57. Thirteen hits with the highest confidence level
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were tested in binding assays and ten compounds were confirmed as 5-HT6R ligands
achieving a success rate of 77%. We noticed that this study design can be applied to many
other protein targets and families of targets involved in the etiology of Alzheimer’s disease.
We shall emphasize that our approach could be used to aid in the process of prioritizing
computational hits that would not be picked by an individual model contributing to the
integrative approach presented in this study. For instance, QSAR/VS hits could emphasize
connections from the cmap that one would not focus on otherwise, especially as the size of
the database continues to grow. In diseases like the Alzheimer’s, with little knowledge about
specific etiology, and the lack of drug gene signatures generated from neuronal cell lines, it
is hard to decide a priori which negative connections are more important to be viewed as
potential therapeutics. Reciprocally, one can use strong connections revealed by cmap to
focus on weak hits resulting from QSAR/VS studies as was demonstrated here for
raloxifene. Thus, integrating hypotheses derived independently from cmap and QSAR
should enable us to increase the confidence in common hits. Herein, we hypothesized and
proved that integrating results generated from the cmap with predictions generated from
QSAR-based VS increased the confidence in the final hit list of predicted actives.
Experimental Section
Radioligand Binding Assays
This screen was performed by the National Institute of Mental Health Psychoactive Drug
Screening Program (PDSP)17. Radioligands were purchased by PDSP from Perkin-Elmer or
GE Healthcare. Competition binding assays were performed using transfected or stably
expressing cell membrane preparations as previously described (Shapiro et al. 200399; Roth
et al. 2002100) and are available online (http://pdsp.med.unc.edu). All experimental details
are available online (http://pdsp.med.unc.edu/UNC-CH%20Protocol%20Book.pdf).
Chemistry
Chemical compounds predicted as hits from the virtual screening were obtained from
commercial suppliers according to their availability. All compounds were ordered to have
above or equal to 95% purity. Additionally, all compounds were subjected to purity
assessment using LC/MS by the Center for Integrative Chemical Biology and Drug
Discovery at UNC-Chapel Hill (see Supporting Information). LC/MS spectra of all
compounds were acquired from an Agilent 6110 Series system with UV detector set to 220
nm. Samples were injected (5 uL) onto an Agilent Eclipse Plus 4.6 × 50 mm, 1.8 uM, C18
column at room temperature. A linear gradient from 10% to 100% B (MeOH + 0.1% Acetic
Acid) in 5.0 min was followed by pumping 100% B for another 2 minutes with A being H2O
+ 0.1% acetic acid. The flow rate was 1.0 mL/min.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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CARs Class Association Rules
CBA Classification Based on Association
CCR Correct Classification Rate
CCRtrain Correct Classification Rate for training set
CCRtest Correct Classification Rate for test set
CCRevs Correct Classification Rate for external validation set
CCRrand Correct Classification Rate of the random models using the external
validation set








HTS High Throughput Screen
kNN k Nearest Neighbor
LOO-CV Leave-One-Out Cross Validation
MFD Most Frequent Descriptors
MOE Molecular Operating Environment
MZ MolConnZ descriptors
PDSP NIMH Psychoactive Drug Screening Program
QSAR Quantitative Structure-Activity Relationships
S1 Alzheimer’s disease gene signature 1








WDI World Drug Index
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Study design for the integrated informatics approach for drug discovery integrating network
mining, text mining of biological literature, the analysis of disease gene signatures and
efficient cheminformatics techniques, to discover novel drugs with desired
polypharmacology.
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The workflow for QSAR model building, validation and virtual screening as applied to 5-
HT6R dataset.
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Comparison of the QSAR approaches to classify 5-HT6R actives vs. non-actives based on
CCRevs.
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QSAR-based virtual screening of two chemical databases: the WDI and DrugBank
compounds included in the cmap.
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Querying the connectivity map with Alzheimer’s disease gene signatures (S1 and S2).
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Integrating hypotheses from QSAR modeling and cmap negative connections.
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Plots for kNN scores vs. cmap connectivity scores for 39 final common hits from QSAR-
based VS and cmap for: (A) Alzheimer’s disease signature S1, and (B) Alzheimer’s disease
signature S2. Squares: compounds predicted and validated as 5-HT6R actives having
negative connectivity scores with Alzheimer’s disease gene signatures; diamonds:
compounds predicted and experimentally validated as 5-HT6R actives but having positive
connectivity scores with one of the Alzheimer’s disease gene signatures; triangles:
compounds predicted as 5-HT6R actives having negative connectivity scores with
Alzheimer’s disease gene signatures but found non-actives in radioligand binding assays
against 5-HT6R; circles: compounds predicted as 5-HT6R actives which have negative
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connectivity scores with Alzheimer’s disease gene signatures but were not experimentally
tested.
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Competition binding isotherms at 5-HT6R for several predicted actives: (A) 2 (red triangle)
and chlorpromazine (square), and 4 (blue triangle) and chlorpromazine (square); (B) 8 (red
triangle) and chlorpromazine (square), and 10 (blue triangle) and chlorpromazine (square);
(C) 13 (triangle) and chlorpromazine (square), versus [3H]LSD.
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Table 1
Top twenty negative connections from the cmap with S1.
Compound Ranka Cell Score Instance_ID
Naproxen 6100 PC3 −1 7146
Sulfacetamide 6099 MCF7 −0.990 1695
Amprolium 6098 HL60 −0.930 1979
Aminoglutethimide 6097 MCF7 −0.913 7463
Ioxaglic acid 6096 HL60 −0.897 2966
Dexpanthenol 6095 MCF7 −0.871 7455
Suxibuzone 6094 MCF7 −0.870 7163
Chlorphenesin 6093 HL60 −0.862 1432
Metixene 6092 HL60 −0.853 2451
Fulvestrant 6091 MCF7 −0.843 5565
Seneciphylline 6090 MCF7 −0.841 2797
Troglitazone 6089 MCF7 −0.839 6991
Dicloxacillin 6088 HL60 −0.834 2445
Phentolamine 6087 HL60 −0.831 2362
Monocrotaline 6086 MCF7 −0.828 6771
Lymecycline 6085 HL60 −0.823 2953
Bezafibrate 6084 PC3 −0.815 6653
6-Benzylaminopurine 6083 HL60 −0.812 2351
Terbutaline 6082 MCF7 −0.811 3202
Clorgiline 6081 MCF7 −0.805 3219
a
The rank order is generated from estimating the connectivity scores of 6100 individual treatment instances with S1. A rank order of 6100
corresponds to the compound with the strongest negative connectivity S1, while a rank order of 1 corresponds to the compound with the strongest
positive connectivity with S1.
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Table 2
Top twenty negative connections from the cmap with S2.
Compound Ranka Cell Score Instance_ID
Trifluoperazine 6100 HL60 −1 2389
1 6099 MCF7 −0.982 4994
Ethotoin 6098 HL60 −0.977 2196
Sulfafurazole 6097 HL60 −0.973 1603
Quercetin 6096 MCF7 −0.964 4846
Triflusal 6095 HL60 −0.925 1717
Alfuzosin 6094 PC3 −0.903 4644
Metitepine 6093 HL60 −0.890 1616
Trioxysalen 6092 MCF7 −0.885 6216
7 6091 MCF7 −0.883 258
Tanespimycin 6090 HL60 −0.873 6184
Spironolactone 6089 MCF7 −0.871 6255
Nifurtimox 6088 MCF7 −0.859 4953
Iobenguane 6087 HL60 −0.847 1729
Undecanoic acid (U0125) 6086 PC3 −0.845 663
Monorden 6085 MCF7 −0.841 5947
Primidone 6084 PC3 −0.833 6723
Calcium pantothenate 6083 MCF7 −0.828 4775
Phthalylsulfathiazole 6082 HL60 −0.826 3033
Ceforanide 6081 PC3 −0.824 6751
a
The rank order is generated from estimating the connectivity scores of 6100 individual treatment instances with S2. A rank order of 6100
corresponds to the compound with the strongest negative connectivity S2, while a rank order of 1 corresponds to the compound with the strongest
positive connectivity with S2.
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Table 4
Therapeutic classes of the thirty nine final computational hits from QSAR-based VS and cmap.
cmap Name Theraputic Class/Use
Acepromazine Antipsychotic
Alimemazine Antipruritic, sedative, hypnotic and anti-emetic
Astemizole Anti-Histamine
Bepridil Calcium channel blocker once used to treat angina
Bromperidol Neuroleptic, used as an antipsychotic in the treatment of schizophrenia
Cetirizine Second-generation antihistamine
Chlorprothixene Typical antipsychotic drug of the thioxanthene class
Cinchocaine Local anesthetic
Cinnarizine Antihistamine which is mainly used for the control of nausea and vomiting due to motion sickness





Diltiazem Calcium channel blocker
4 Psychotropic agent with tricyclic antidepressant and anxiolytic properties
5 Calcium channel blocker
Flavoxate Anticholinergic with antimuscarinic effects
6 Antipsychotic
Imipramine Tricyclic antidepressant
Laudanosine Benzyltetrahydroisoquinoline alkaloid. Interacts with GABA, opioid, and nicotinic acetylcholine receptors
7 Morpholino derivative of quercetin. It is a potent inhibitor of phosphoinositide 3-kinase s (PI3Ks)
Meclozine Antihistamine considered to be an antiemetic
Mepacrine Antiprotozoal, antirheumatic and an intrapleural sclerosing agent. It is known to act as a histamine N-
methyltransferase inhibitor
Methylergometrine Psychedelic alkaloid
Naftifine Allylamine antifungal drug
8 Second-generation tricyclic antidepressant
Phenoxybenzamine Non-specific, irreversible alpha antagonist
Piperidolate Antimuscarinic.
9 Drug used in scientific research which acts as a moderately selective dopamine D3 receptor partial agonist.




Telenzepine Anticholinergic or sympatholytic
Terfenadine Antihistamine formerly used for the treatment of allergic conditions
Vanoxerine Piperazine derivative which is a potent and selective dopamine reuptake inhibitor (DRI)
Vinpocetine Vinpocetine has been identified as a potent anti-inflammatory agent that might have a potential role in the
treatment of Parkinson's disease and Alzheimer’s disease80;81
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cmap Name Theraputic Class/Use
13 Typical antipsychotic drug
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Table 6
The significance of the tested hits in relation to cognition, neuroprotection and anti-Alzheimer’s effects.
Compound Predicted Ki Significance to Alzheimer’s disease prevention/treatment
1 Active 1956.0 Unknown
2 Active 112.0 Neuroprotective101
3 Active 17.0 Used in combination therapy for Alzheimer’s102
4 Active 105.0 Unknown
5 Active NB GABA receptor modulator103;104 and may inhibit amyloid-beta protein oligomerization as other related
antihypertensives105
6 Active 1188.0 Possible anti-Alzheimer’s effects 106
7 Active NB Can inhibit central sensitization and neuroinflammation107;108
8 Active 214.0 Possible anti-Alzheimer’s effects 109
9 Active NB Unknown
10 Active 750.0 Possible anti-Alzheimer’s effects 96
11 Active 1041.0 Neuroprotective110
12 Active 4125.0 Unknown
13 Active 169.0 Facilitates memory in rats111
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